PYXS
Pyxis Oncology·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PYXS
Pyxis Oncology, Inc.
A diversified oncology company focused on developing therapeutics to target difficult-to-treat cancers
321 Harrison Avenue
Boston
Massachusetts 02118
Develops cancer drugs and therapies.
Pyxis Oncology, Inc., was incorporated in Delaware on June 11, 2018. The company is a clinical-stage oncology company advancing a development strategy focused on addressing the unmet medical needs of patients with solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC).
Company Financials
EPS
PYXS has released its 2026 Q2 earnings. EPS was reported at -0.4, versus the expected -0.35, missing expectations. The chart below visualizes how PYXS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
